<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03762018</url>
  </required_header>
  <id_info>
    <org_study_id>ETOP 13-18</org_study_id>
    <secondary_id>2018-002180-25</secondary_id>
    <secondary_id>MO40388</secondary_id>
    <nct_id>NCT03762018</nct_id>
  </id_info>
  <brief_title>BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma</brief_title>
  <acronym>BEAT-meso</acronym>
  <official_title>A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Thoracic Oncology Platform</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to assess the effect of treatment with a monoclonal
      antibody called atezolizumab in patients diagnosed with a type of lung cancer called
      malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and
      tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with
      standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be
      investigated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer arising from the
      mesothelial surface of the pleura. In Europe, the incidence is about 20 per million and is
      almost always caused by asbestos exposure, with a usual lag time of 30 years between exposure
      and presentation. Patients diagnosed with advanced MPM have limited treatment options,
      representing a strict unmet need. Despite decades of clinical research, cytotoxic
      chemotherapy remains one of the few therapeutic options that has been proven to improve
      survival in advanced MPM in a randomised controlled trial.

      The combination of cisplatin and pemetrexed has become standard first-line therapy worldwide
      for patients who are not suitable for aggressive surgery or in whom chemotherapy is
      recommended as part of a multimodality regimen. Carboplatin is often substituted for
      cisplatin, due to simpler and shorter administration and assumption of a more favourable
      toxicity profile based on experience in other diseases. Patients with MPM have limited
      treatment options, representing a strict unmet need.

      An antibody is a common type of protein usually made in the body in response to a foreign
      substance. Antibodies attack foreign substances and protect against infection. The two
      monoclonal antibodies (atezolizumab and bevacizumab) used in this trial are
      laboratory-produced antibodies. Atezolizumab is engineered to attach to immune cells to
      stimulate their activity against cancer cells.

      Atezolizumab and bevacizumab are both approved by the European Medicines Agency for the
      treatment of lung and other cancers. The addition of atezolizumab to bevacizumab plus
      standard chemotherapy for the treatment of MPM is being investigated in this trial.

      All participants will receive 4-6 cycles of standard chemotherapy consisting of carboplatin
      AUC 5 (area under the plasma concentration versus time curve) plus pemetrexed 500mg/m^2 given
      intravenously, on day 1 of every 3 week cycle for about 12 to 18 weeks.

      Participants will be randomly assigned to one of two treatment groups:

      Treatment 1

        -  Bevacizumab 15 mg/kg intravenously on day 1 of every 3-week cycle, plus

        -  4-6 cycles of chemotherapy

      OR

      Treatment 2

        -  Atezolizumab 1200 mg fixed dose intravenously on day 1 of every 3-week cycle, plus

        -  Bevacizumab 15 mg/kg, intravenously on day 1 of every 3-week cycle, plus

        -  4-6 cycles of chemotherapy

      Participants will continue to receive treatment until disease progression, or until treatment
      is stopped at the request of the participant or treating doctor, or the participant withdraws
      consent.

      A total of 320 participants from approximately 45 centres in Europe are expected to be
      included in this trial which will take approximately 6 years to be completed after the first
      participant is enrolled.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) according to the mRECIST v1.1</measure>
    <time_frame>From date of randomisation until documented progression or death, if progression is not documented, assessed up to 67 months</time_frame>
    <description>A co-primary endpoint, defined as the time from the date of randomisation until documented progression (according to the mRECIST v1.1) or death, if progression is not documented. Censoring (for participants without a PFS/death event) will occur at the last tumour assessment if the patient is lost to follow-up or refuses further documentation of follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of randomisation until death from any cause, assessed up to 67 months</time_frame>
    <description>The second co-primary endpoint, overall survival, is defined as the time from the date of randomisation until death from any cause. Censoring will occur at the last follow-up date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response (OR)</measure>
    <time_frame>From start of protocol treatment accorss all time-points until end of protocol treatment, assessed up to 67 months</time_frame>
    <description>Defined as the best overall response [complete response (CR) or partial response (PR)] evaluated according to the mRECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC) at 24 weeks</measure>
    <time_frame>24 weeks after protocol treatment start</time_frame>
    <description>Defined as complete or partial response, or disease stabilisation at 24 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>From randomisation until discontinuation of protocol treatment for any reason, assessed up to 67 months</time_frame>
    <description>Defined as the time from the date of randomisation to discontinuation of protocol treatment for any reason (including progression of disease, treatment toxicity, refusal and death). Censoring will occur at the last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From date of first documentation of objective response until date of first documented progression or relapse, assessed up to 67 months</time_frame>
    <description>Defined as the interval from the date of first documentation of objective response (complete response or partial response, according to the mRECIST v1.1) to the date of first documented progression or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse events according to Common Toxicity Criteria for Adverse Events (CTCAE) v5.0</measure>
    <time_frame>Assessed from the date of informed consent until 90 days after protocol treatment discontinuation. Analysed at 67 months after randomisation of the first patient</time_frame>
    <description>Assessed through analysis of the worst grade of toxicity/adverse events and will include all participants who received at least one dose of protocol treatment. Adverse events leading to dose interruption, withdrawal of protocol treatment and deaths, laboratory parameters and abnormalities and vital signs over the whole treatment period will be assessed and graded according to CTCAE v5.0 criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Pleural Mesothelioma Malignant Advanced</condition>
  <arm_group>
    <arm_group_label>Bevacizumab plus chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab plus bevacizumab plus chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m^2 intravenously on day 1 every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin belongs to the group of medicines known as alkylating agents. Carboplatin interferes with the growth of cancer cells, which eventually are destroyed.</description>
    <arm_group_label>Atezolizumab plus bevacizumab plus chemotherapy</arm_group_label>
    <arm_group_label>Bevacizumab plus chemotherapy</arm_group_label>
    <other_name>Carboplatin Accord</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed is a type of drug known as an anti metabolite. It stops cells making and repairing DNA so they can't grow and multiply.</description>
    <arm_group_label>Atezolizumab plus bevacizumab plus chemotherapy</arm_group_label>
    <arm_group_label>Bevacizumab plus chemotherapy</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is an angiogenesis inhibitor. It works by targeting a protein called vascular endothelial growth factor (VEGF) that helps cancers form new blood vessels. By stopping this process, bevacizumab 'suffocates' the blood supply to the cancer, shrinking it and stopping it from growing.</description>
    <arm_group_label>Atezolizumab plus bevacizumab plus chemotherapy</arm_group_label>
    <arm_group_label>Bevacizumab plus chemotherapy</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain protein in cancer cells. This helps the immune system to fight against the cancer cells, and helps to slow tumor growth.</description>
    <arm_group_label>Atezolizumab plus bevacizumab plus chemotherapy</arm_group_label>
    <other_name>Tecentriq</other_name>
    <other_name>RO5541267</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced malignant pleural mesothelioma (all histological
             subtypes are eligible)

          -  Not amenable for radical surgery based on local standards

          -  Evaluable disease or measurable disease as assessed according to the modified response
             evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1

          -  Availability of tumour tissue for translational research

          -  Age &gt;18 years

          -  Performance Status 0-1

          -  Life expectancy &gt;3 months

          -  Adequate haematological, renal and liver function

          -  Completed baseline quality of life (QoL) questionnaire

          -  Women of childbearing potential and sexually active men must agree to use highly
             effective contraception

          -  Able to understand and give written informed consent and comply with trial procedures

        Exclusion Criteria:

          -  Prior treatment for malignant pleural mesothelioma

          -  Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of
             the drug prior to randomisation and during protocol treatment.

          -  Treatment with systemic immunosuppressive medications within 2 weeks prior to
             randomisation and during protocol treatment.

          -  Previous allogeneic tissue/solid organ transplant

          -  Live vaccines within 4 weeks prior to first dose of protocol treatment

          -  Inadequately controlled hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  Significant vascular disease within 6 months prior to randomisation

          -  History of haemoptysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enriqueta Felip, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vall d'Hebron University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanjay Popat, PhD, MBBS</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Ruepp, PharmD</last_name>
    <phone>+41 31 511 94 00</phone>
    <email>barbara.ruepp@ibcsg.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence Berger, PhD</last_name>
    <phone>+41 31 511 94 48</phone>
    <email>BEAT-meso@etop-eu.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristiaan Nackaerts, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kristiaan Nackaerts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liege</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Duysinx, MD</last_name>
      <phone>0032 43668181</phone>
      <email>bduysinx@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Bernard Duysinx, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unicancer - Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cousin Sophie, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cousin Sophie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen- CHU</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Youssef Oulkhouir, MD</last_name>
    </contact>
    <investigator>
      <last_name>Youssef Oulkhouir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Mans - CHG</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Molinier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Molinier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lyon - Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maurice Pérol</last_name>
    </contact>
    <investigator>
      <last_name>Maurice Pérol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Greillier, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent Greillier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Curie Cancer Center Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie B Danel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie B Danel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse - CHU</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Mazières, MD</last_name>
    </contact>
    <investigator>
      <last_name>Julien Mazières, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours - CHU</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Pichon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Pichon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SS Antonio e Biagio e Cesare Arrigo Hospital</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federica Grosso</last_name>
    </contact>
    <investigator>
      <last_name>Federica Grosso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Instituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annamaria Catino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Annamaria Catino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale die Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina C Garassino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marina C Garassino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia (IEO)</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo de Marinis, MD</last_name>
    </contact>
    <investigator>
      <last_name>Filippo de Marinis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AULSS2 Marca Trevigiana Treviso</name>
      <address>
        <city>Treviso</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adolfo Favaretto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adolfo Favaretto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Turin</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Novello, MD</last_name>
    </contact>
    <investigator>
      <last_name>Silvia Novello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alicante University Hospital ISABIAL</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartomeu Massuti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bartomeu Massuti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Nadal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ernest Nadal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall Hebron University Hospital/Vall Hebron Institue Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana C Perez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Susana C Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerta de Hierro Hospital</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Provencio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mariano Provencio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli Sabadell</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda G Garcia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yolanda G Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Bernabé, MD</last_name>
    </contact>
    <investigator>
      <last_name>Reyes Bernabé, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Vigo</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin C Rubio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joaquin C Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janthur Wolf-Dieter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Janthur Wolf-Dieter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologica della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Froesch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Froesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Scherz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amina Scherz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mark, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michael Mark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange Peters, MD</last_name>
    </contact>
    <investigator>
      <last_name>Solange Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Lucerne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Gautschi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Oliver Gautschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Früh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Martin Früh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miklos Pless, MD</last_name>
    </contact>
    <investigator>
      <last_name>Miklos Pless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Curioni Fontecedro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Curioni Fontecedro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gilligan, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Gilligan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Cancer Centre</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Pope, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony Pope, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Spicer, MD</last_name>
    </contact>
    <investigator>
      <last_name>James Spicer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (Fulham Road)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sanjay Popat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital (Sutton)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Popat, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sanjay Popat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kent Oncology Centre</name>
      <address>
        <city>Maidstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riyaz Shah, MD</last_name>
    </contact>
    <investigator>
      <last_name>Riyaz Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wythenshawe Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Cove Smith, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laura Cove Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Roy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amy Roy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Fisher, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patricia Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toby Talbot, MD</last_name>
    </contact>
    <investigator>
      <last_name>Toby Talbot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Portugal</country>
    <country>Slovenia</country>
  </removed_countries>
  <reference>
    <citation>Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003 Jul 15;21(14):2636-44.</citation>
    <PMID>12860938</PMID>
  </reference>
  <reference>
    <citation>Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-1414. doi: 10.1016/S0140-6736(15)01238-6. Epub 2015 Dec 21. Erratum in: Lancet. 2016 Apr 2;387(10026):e24.</citation>
    <PMID>26719230</PMID>
  </reference>
  <reference>
    <citation>Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013 Aug 6;109(3):552-8. doi: 10.1038/bjc.2013.368. Epub 2013 Jul 16.</citation>
    <PMID>23860535</PMID>
  </reference>
  <reference>
    <citation>Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973. Review.</citation>
    <PMID>26205340</PMID>
  </reference>
  <reference>
    <citation>Soto-Ortiz L, Finley SD. A cancer treatment based on synergy between anti-angiogenic and immune cell therapies. J Theor Biol. 2016 Apr 7;394:197-211. doi: 10.1016/j.jtbi.2016.01.026. Epub 2016 Jan 27.</citation>
    <PMID>26826488</PMID>
  </reference>
  <reference>
    <citation>Wallin JJ, Bendell JC, Funke R, Sznol M, Korski K, Jones S, Hernandez G, Mier J, He X, Hodi FS, Denker M, Leveque V, Cañamero M, Babitski G, Koeppen H, Ziai J, Sharma N, Gaire F, Chen DS, Waterkamp D, Hegde PS, McDermott DF. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016 Aug 30;7:12624. doi: 10.1038/ncomms12624.</citation>
    <PMID>27571927</PMID>
  </reference>
  <reference>
    <citation>Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol. 2007 Jun;4(6):344-52. Review.</citation>
    <PMID>17534390</PMID>
  </reference>
  <reference>
    <citation>Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. doi: 10.1038/ncponc1039. Review.</citation>
    <PMID>18227828</PMID>
  </reference>
  <reference>
    <citation>Nowak AK. Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg. 2012 Nov;1(4):508-15. doi: 10.3978/j.issn.2225-319X.2012.10.05.</citation>
    <PMID>23977545</PMID>
  </reference>
  <reference>
    <citation>Armato SG 3rd, Nowak AK. Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). J Thorac Oncol. 2018 Jul;13(7):1012-1021. doi: 10.1016/j.jtho.2018.04.034. Epub 2018 May 9. Erratum in: J Thorac Oncol. 2019 Mar;14(3):560.</citation>
    <PMID>29753121</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 20, 2018</study_first_submitted>
  <study_first_submitted_qc>November 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2018</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

